Effects of the SGLT-2 Inhibitor Empagliflozin on Renal Tissue Oxygenation in Non-Diabetic Subjects: A Randomized, Double-Blind, Placebo-Controlled Study Protocol

INTRODUCTION: Empagliflozin is an SGLT-2 inhibitor (SGLT-2i) which belongs to a new class of hypoglycemic drugs with the unique property of decreasing blood glucose independently from insulin, through an increase in glycosuria. In addition to decreasing cardiovascular morbidity and mortality, empagl...

Descripción completa

Detalles Bibliográficos
Autores principales: Muller, Marie-Eve, Pruijm, Menno, Bonny, Olivier, Burnier, Michel, Zanchi, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015115/
https://www.ncbi.nlm.nih.gov/pubmed/29802538
http://dx.doi.org/10.1007/s12325-018-0708-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015115/
https://www.ncbi.nlm.nih.gov/pubmed/29802538
http://dx.doi.org/10.1007/s12325-018-0708-y

Ejemplares similares